Skip to content
Roche is investing $550 million into its diagnostics campus in Indianapolis, further cementing the city as the North American headquarters of Roche Diagnostics—part of the world’s largest biotech company.
The expansion includes a new manufacturing facility for Roche’s continuous glucose monitoring (CGM) systems, addressing the growing needs of more than 38 million Americans living with diabetes. CGM technology plays a vital role in daily disease management, and this move supports Roche’s mission to improve patient care through innovation.
The Indianapolis site already serves as a major hub, producing around 5.2 billion Accu-Chek diabetes test strips annually and supporting distribution to 53 countries. It also houses research, laboratories, IT, manufacturing, and administrative operations.
This latest investment is expected to create hundreds of skilled manufacturing jobs and thousands of construction roles, strengthening Indiana’s economy while reducing reliance on imported medical technologies. It follows Roche’s broader plan to invest $50 billion into the US over the next five years.
Read the full story here.
Want more stories like this? Subscribe to our newsletter and stay ahead with the latest in the lab world.
